Tirzepatide

Tirzepatide, the same active ingredient in Mounjaro®, represents the latest and most potent GLP-1 class medication for sustained weight loss. Patients have experienced an impressive average weight reduction of 24.3% over 72 weeks, in conjunction with a calorie-restricted diet and heightened physical activity. This dual-action GLP-1/GIP is for individuals with obesity (BMI ≥30) or overweight (BMI ≥27) accompanied by a weight-related condition, alongside dietary and exercise modifications.